The Mass Balance and Biotransformation of [14C] Vicagrel in Healthy Man

The Mass Balance and Biotransformation Study of [14C] Vicagrel in Chinese Healthy Adult Male Volunteers

This study was designed to evaluate the mass balance and biotransformation after single-dose of [14C]Vicagrel orally in Chinese healthy male volunteers, revealing the overall pharmacokinetic characteristics of vicagrel in humans, and providing a reference for the rational administration.

Study Overview

• Status: Completed
• Conditions: Healthy Male Adult
• Intervention / Treatment: Drug: [14C]Vicagrel

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Suzhou, Jiangsu, China
      • The first affiliated hospital of suzhou University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• A healthy male adult.
• Age is between 18 and 45, inclusive.
• Body mass index is between 19 and 26, inclusive.
• Voluntarily to provide informed consent form.
• Willing and able to communicate with investigators and complete the trial according to clinical trial protocol.

Exclusion Criteria:

• Any abnormal and clinical significant findings to physic exam, vital sign, electrocardiogram, X-ray exam for chest, laboratory exam including blood biochemical, blood routine, blood coagulation, urine routine, routine stool plus occult blood and thyroid stimulating hormone, and so on.
• A positive examination result of HBsAg/HBeAg, HIV antibody and treponema pallidum antibody.
• Volunteers who take any medicines including OTC, hormone birth control and/or alternative medicines such as medicated diets, Chinese herbal medicines, hemostatics or supplements within 14 days before the screening.
• Volunteers have clinical product administration or clinical trial participation within 3 months before the screening.
• Any history of clinical serious disease, or presence illness/condition that, in the opinion of the investigator, would jeopardize the study results, including but not limited to the circulatory system, endocrine system, nervous system, digestive system, urinary system or history of blood, immune, mental and metabolic diseases.
• History of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsade ventricular tachycardia, ventricular tachycardia, QT prolongation syndrome, or QT prolongation Symptoms and family history ,indicated by genetic evidence or sudden death of a close relative due to cardiac conditions at a young age.
• Volunteers or their immediate family have coagulopathy, coagulative/hemorrhagic disease ,such as hemophilia, gastrointestinal bleeding, cyanosis, coagulative /hemorrhagic symptoms ,such as hematemesis, melena, severe or recurrent epistaxis, hemoptysis, obvious hematuria or intracranial hemorrhage, coagulative/hemorrhagic family history, suspected vascular malformations, such as aneurysm or early onset stroke, CVA < 65 years old, bleeding tendency ,such as repeated bleeding gums, or previous active pathological bleeding.
• Current or recent (<6 months) disease of dyspepsia, esophageal reflux, stomach bleeding, peptic ulcer, often heartburn over one times every week or any surgery that may affect drug absorption , such as cholecystectomy.
• Major surgery or surgical incision did not completely heal within 6 months before the screening. Major surgery includes, but is not limited to, any volunteer with significant bleeding risk, prolonged general anesthesia, incision of a biopsy or significant traumatic injury.
• Ecchymoses were detected in the skin during physical examination.
• The prothrombin time (PT) and/or activated partial thromboplastin time (APTT) exceeds the upper limit of the normal range, or the hematocrit (HCT) or platelet count (PLT) is out of the normal range.
• Volunteers who are allergic to drugs, the same type of investigational product ,such as clopidogrel, ticagrelor, etc., pharmaceutical excipients, alcohol, food ingredients. Or who has special requirements for diet and cannot comply with the required diet.
• Suffering acne or perianal disease in blood in the stool or regularly.
• Volunteers have habitual constipation, diarrhea, irritable bowel syndrome or inflammatory bowel disease.
• Volunteers are alcoholism, often drinking in six months before screening which means more than 14 units of alcohol every week, or the alcohol breath test result is positive in screening. One unit alcohol equals 360 mL of beer, 45 mL of 40% alcohol or 150 mL of wine.
• Volunteers have daily smoking exceeds 5 cigarettes in three months before screening, or habitual use of nicotine products, and can not be withdrawn during the trial.
• Abusing drug, using soft drugs such as marijuana three months prior to screening, using hard drugs such as cocaine, amphetamine, phencyclidine, etc. one year prior to screening; or urine test for drugs is positive in screeing.
• Volunteers have habitual drinking of grapefruit juice, excessive tea, coffee and/or caffeinated beverages, and who can not be abstained during the trial.
• Volunteers who have to work in radioactive conditions in long time, participated in radio-labeled drug clinical trial or had significant radioactive exposure within one year before the trial, more than 2 times of chest/abdominal CT, or more than 3 times of different types of X-ray exam.
• Volunteer and their spouse who have a birth plan or who are unwilling to take strict contraceptive measures such as condoms, contraceptive sponges, contraceptive gels, contraceptive film, intrauterine device, contraceptive for oral and injection, subcutaneous implant, etc., during the trial or in the future one year after the trial.
• Volunteers, who have had blood loss/donation up to 400 mL within 3 months before the screening, or received blood transfusion within 1 month.
• Volunteers are not suitable for this clinical trial, in the opinions of investigators.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: [14C]Vicagrel	Drug: [14C]Vicagrel; Take a suspension of 20 mg vicagrel ,containing about 120 μCi [14C]Vicagrel, in fasting within 5 minutes

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total radioactive datas in blood	Total radioactive distribution and pharmacokinetics in blood and plasma	from 0 hour to 240 hours after administration
Total radioactive datas in excreta	Total radioactive distribution and pharmacokinetics in urine and feces; the main routes of [14C]Vicagrel excretion in human	from 0 hour to 240 hours after administration
Peak Plasma Concentration (Cmax)	Determine the Cmax of Vicagrel metabolites M3, M9-2, M15-1 and M15-2 in plasma	from 0 hour to 240 hours after administration
Area under the plasma concentration versus time curve (AUC)	Determine the AUC of Vicagrel metabolites M3, M9-2, M15-1 and M15-2 in plasma	from 0 hour to 240 hours after administration
Time of Peak Plasma Concentration(Tmax)	Determine the Tmax of Vicagrel metabolites M3, M9-2, M15-1 and M15-2 in plasma	from 0 hour to 240 hours after administration
Drug half-life in plasma(t1/2)	Determine the T1/2 of Vicagrel metabolites M3, M9-2, M15-1 and M15-2 in plasma	from 0 hour to 240 hours after administration
Mean Residence Time (MRT)	Determine the MRT of Vicagrel metabolites M3, M9-2, M15-1 and M15-2 in plasma	from 0 hour to 240 hours after administration
Numbers of Vicagrel Metabolites	Detect Vicagrel Metabolites in blood, feces and urines as much as possible to clear the main routes of biotransformation	from 0 hour to 240 hours after administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events	Review the relationship between investigational products and all the abnormal and clinically significant findings	through the completion of study, an average of 2 months

Collaborators and Investigators

• Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

Study record dates

Study Major Dates

• Study Start (Actual): November 11, 2019
• Primary Completion (Actual): December 29, 2019
• Study Completion (Actual): January 14, 2020

Study Registration Dates

• First Submitted: October 21, 2019
• First Submitted That Met QC Criteria: October 27, 2019
• First Posted (Actual): October 29, 2019

Study Record Updates

• Last Update Posted (Actual): April 3, 2020
• Last Update Submitted That Met QC Criteria: April 1, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: 2018-MB-WKGL-08

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No